



SCIENTIFIC PROGRAM

(Preliminary Draft - December 9, 2025)

(The Current Sessions and Presentations are in Eastern Standard Time and Subject to Change)

TUESDAY, OCTOBER 6, 2026

8:00AM

WELCOME AND INTRODUCTION

Faina Shtern, MD, President and CEO, AdMeTech Foundation

8:15AM

SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION

Moderators:

Peter Albers, MD, Chairman, Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf and Division Head, Division of Personalized Early Detection of Prostate Cancer at the German Cancer Research Center (DKFZ), Heidelberg University, Germany

Sigrid Carlsson, MD, PhD, MPH, Division Head, Clinical Epidemiology of Early Cancer Detection, DKFZ, Heidelberg University, Germany

Stenio Zequi, MD, MSc, PhD, Head of Referral Center for Urological Tumors, A.C. Camargo Cancer Center, Brazil

8:30AM

Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening

8:30AM

Topic 1A: Advancing Risk-Stratified Screening and Early Detection: Sigrid Carlsson, MD, PhD, MPH

8:40AM

Q & A

8:42AM

Topic 1B: Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50): Peter Albers, MD

8:52AM

Q & A

8:54AM

Topic 1C: Update on PRAISE-U Project – European Union Initiative in PC Screening: Monique Roobol, PhD, Professor of Decision Making in Urology and the Head of the Scientific Research Office, Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands

9:04AM

Q & A

9:06AM

Topic 1D: Organized Prostate Testing (OPT) in Sweden: Anders Bjartell, MD, PhD, FEBU, Professor in Urology, Department of Translational Medicine, Lund University; and Senior Consultant, Skane University Hospital, Sweden

9:16AM

Q & A

9:18AM

Topic 1E: TRANSFORM - National UK Trial of Prostate Cancer Screening: Rhian Gabe, PhD, Professor of Biostatistics and Clinical Trials, Director of Barts Clinical Trials Units, Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom

9:28AM

Q & A

9:30AM-10:00AM

Panel Discussion: “Smart” Prostate Cancer Screening

10:00AM-10:30AM

COFFEE BREAK

10:30AM	SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
	Moderators:
	Preston Sprenkle, MD, Associate Professor of Surgery, Yale University School of Medicine; and Vice Chair, NCCN Prostate Cancer Early Detection Panel
	Clare M. C. Tempany-Afdhal, MB, BAO, BCh, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women's Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Immediate Past Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization (TBC)
10:30AM	Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
10:30AM	<i>Topic 2A: Current and Emerging Liquid Diagnostics</i>
10:30AM	Overview of Liquid Biomarkers: E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Urology Today; and Prostate Cancer Series Editor, Oncology Journal
10:40AM	Q & A
10:42AM	Large-Scale, Prospective, Clinical Validation Study of the Diagnostic Performance of IsoPSA Without and In Combination with Mutli-Parametric MRI for the Detection of High-Grade Prostate Cancer: Mark Stovsky, MD, MBA, FACS, Chief Medical Officer, Cleveland Diagnostics, Inc. Sponsored by Cleveland Diagnostics
10:48AM	Q & A
10:50AM	<i>Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies</i>
10:50AM	OPTIMUM Trial – A 3-Arm Randomized Controlled Clinical Study Evaluating the Role of Micro-Ultrasound in Men with Clinical Suspicion of Prostate Cancer: Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation
11:00AM	Q & A
11:02AM	MRI PI-RADS Standardization and Clinical Evaluation: Clare Tempany, MB, BAO, BCh (TBC)
11:12AM	Q & A
11:14AM	A Calibration Tool for ADC Measurements in Prostate Cancer: Xavier Golay, PhD, MS, Honorary Professor of MRI Physics, University College London, UK
11:24AM	Q & A
11:26AM	<i>Topic 2C: State of the Art and Future Directions in Prostate Biopsies</i>
11:26AM	Urologic Perspective: Alastair Lamb, MD, PhD, FRCS, CRUK Advanced Clinician Scientist Fellow, Barts Cancer Institute, Queen Mary University of London; Honorary Consultant Urological Surgeon, Guy's Hospital; and Visiting Associate Professor, University of Oxford, United Kingdom (TBC)
11:36AM	Q & A
11:38AM	Role of MRI-Targeted Biopsy in Optimizing Prostate Cancer Diagnosis: Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University
11:48AM	Q & A
11:50AM	<i>Topic 2D: Do Biopsies Account for Some of the Progression We See After Prostate Cancer Treatments?</i> Mark Emberton, MD, Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom
12:00PM	Q & A

12:02PM-12:30PM	<i>Panel Discussion: Current and Emerging Diagnostic Tools</i>
12:30PM	Topic 3: Newly Identified Mutations Associated with Prostate Cancer Risk and Aggressiveness: Brian T. Helfand, MD, PhD, Ronald L. Chez Family and Richard Melman Family Endowed Chair in Prostate Cancer, and Clinical Professor, University of Chicago, Pritzker School of Medicine, NorthShore University HealthSystem, Endeavor Health
12:40PM	Q & A
12:42PM	Topic 4: NCCN Guidelines for Early Detection of Prostate Cancer 2025: Preston Sprenkle, MD
12:52PM	Q & A
12:54PM-1:30PM	General Discussion – Moderators and Speakers
1:30PM-2:00PM	VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)
2:00PM-3:00PM	LUNCH BREAK
3:00PM	PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT Moderators: Paul Boutros, PhD, MBA, Director of the NCI-Designated Cancer Center at Sanford Burnham Prebys; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA Amita Dave, PhD, Vice-Chair, Radiology-Medical Physics Outreach; Deputy Service Chief for Predictive Informatics, and Director of Quantitative Imaging, Department of Radiology, Memorial Sloan Kettering Cancer Center
3:00PM	<i>AI and Big Data: What's Close and What's Far Away?:</i> Paul Boutros, PhD, MBA
3:10PM	Q & A
3:12PM	<i>How Artificial Intelligence and Deep Learning Algorithms Can Help with Prostate MRI:</i> Mukesh Harisinghani, MD, Professor of Radiology, Harvard Medical School; and Director of Body Translational MRI, and Director of the Clinical Discovery Program Center for Molecular Imaging Research, Massachusetts General Hospital (TBC)
3:22PM	Q & A
3:24PM	<i>AI, Bioinformatics and Prostate Cancer Care:</i> Ilya Gipp, MD, PhD, Chief Medical Officer - Oncology, GE Healthcare, Sponsored by GE Healthcare
3:34PM	Q & A
3:36PM-5:30PM	<i>Panel Discussion: Moderators and Speakers</i>

WEDNESDAY, OCTOBER 7, 2026

8:00AM **SESSION II (PART 1). CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER**

Moderators:

Alberto Vargas, MD, Professor and Vice Chair, Department of Radiology, New York University (TBC)

Mohammed Shahait, MD, Assistant Professor of Clinical Urology, Department of Urology, University of California, Irvine

Lalitha K. Shankar, Acting Associate Director, Cancer Imaging Program; and Chief, Clinical Trials Branch, National Cancer Institute, National Institutes of Health (TBC)

8:05AM	Topic 1: Multiomics for Prostate Cancer
8:05AM	<i>Topic 1A: Clinical and Prognostic Implications of Cancer Visibility on Imaging</i>
8:05AM	MRI: Alberto Vargas, MD, Professor and Vice Chair, Department of Radiology, New York University (TBC)
8:15AM	Q & A
8:17AM	Molecular Imaging: Professor Michael Hofman, MBBS, FRACP, FAANMS, FICIS, FSNM, FAHMS, GAICD, PET/CT Head, Cancer Imaging; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC); Peter MacCallum Cancer Centre, Melbourne; and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia (TBC)
8:27AM	Q & A
8:29AM	<i>Topic 1B: Urologic Perspective: Genomics and Natural History of MRI Invisible vs Visible Cancers: Laurence Klotz, MD</i>
8:39AM	Q & A
8:41AM	<i>Topic 1C: PSMA Imaging-Guided Salvage Radiotherapy in Patients with Biochemical Recurrence after Radical Prostatectomy-Emerging Five-Year Outcomes: Andrea Di Giorgio, MD, Nuclear Medicine Unit - University of Bologna, and University of Bologna Medical Center, Italy</i>
8:51AM	Q & A
8:53AM	<i>Topic 1D: Novel and Emerging Pathological Factors in Localized and Recurrent Prostate Cancer: Gladell P. Paner, MD, Professor of Pathology and Surgery (Urology), and Director of Genitourinary Pathology Service, University of Chicago</i>
9:03AM	Q & A
9:05AM	<i>Topic 1E: Integration of MRI with Histology, Genomics, and Proteomics: Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA</i>
9:15AM	Q & A
9:17AM-9:40AM	<i>Panel Discussion: Multiomics – Moderators and Speakers</i>
9:40AM-10:30AM	COFFEE BREAK
10:30AM	SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
	Moderators:
	Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF (TBC)
	Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign
10:30AM	Topic 2: Year in Review - Emerging Advances in Diagnosis and Treatment: Matthew Cooperberg, MD, MPH (TBC)
10:40AM	Q & A
10:42AM	Topic 3: Old School, New Insight: Histomorphology in the Modern Biomarker Era of Risk Stratification of Prostate Cancer: Jane Nguyen, MD, PhD, Assistant Professor of Pathology at the Case Western Reserve University/Lerner College of Medicine; Director of Genitourinary Pathology; Staff Pathologist in the Diagnostics Institute, Department of Pathology and Laboratory Medicine at the Cleveland Clinic
10:52AM	Q & A
10:54AM	Topic 4: The Future of PSMA PET Imaging: Ashley E. Ross, MD, PhD, Associate Professor of Urology and Clinical Director, Polsky Urologic Oncology Center, Northwestern Feinberg School of Medicine

11:04AM	Topic 5: Integration of Precision Diagnosis and Precision Treatment
11:06AM	<i>Topic 5A: Integrated Diagnostics (Radiogenomics) for Active Surveillance, Surgical and Radiation Treatment:</i> Sanoj Punnen, MD, MAS, MBA, Professor of Urology, and Vice Chair of Research, Desai Sethi Urology Institute; and Assistant Director of Clinical Research and Cancer Control Research Program Co-Lead, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine
11:16AM	Q & A
11:18AM	<i>Topic 5B: Image-Guided, Minimally-Invasive Focal Treatment: Emerging Role in Patient Management:</i> John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine (TBC)
11:28AM	Q & A
11:30AM	<i>Topic 5C: Radiation Treatment:</i> Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University (TBC)
11:40AM	Topic 6: Optimal Management of Patients Presenting with Locally Advanced Prostate Cancer in 2026: Raja B. Khauli, MD
11:50AM	Q & A
11:52AM	Topic 7: Recurrent Disease
11:52AM	<i>Topic 7A: Principles of Focal Salvage Treatment for Radiorecurrent Prostate Cancer – Is it Feasible?:</i> Giancarlo Marra, MD, Consultant Urologist and Assistant Professor, Division of Urology, AOU Citta Della Salute e Della Scienza and University of Turin, Italy
12:02PM	Q & A
12:04PM	<i>Topic 7B: NCI Working Group Recommendations on Biomedical Cancer Recurrence:</i> David Einstein, MD, Assistant Professor, Harvard Medical School, and Attending Physician, Beth Israel Deaconess Medical Center Genitourinary Medical Oncology Program
12:14PM	Q & A
12:16PM	<i>Topic 7C: Clinical Role of PET/MRI in Biochemical Recurrence:</i> Hong Song, MD, PhD, Assistant Professor, Nuclear Medicine and Radiology, Stanford University (TBC)
12:26PM	Q & A
12:28PM-12:50PM	<i>Panel Discussion: Integration of Precision Diagnosis and Treatment</i>
12:50PM-1:45PM	VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)
1:45PM-2:15PM	LUNCH BREAK
2:15PM	SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
	Moderators:
	Steven Eric Finkelstein, MD, DABR, FACRO, National Director of the Center of Advanced Radiation Excellence (CARE) and Director, Radiation Oncology Research, Associated Medical Professionals / US Urology, Syracuse, NY; and Board of Chancellors and Chair of Education Committee, American College of Radiation Oncology (ACRO)
	Katherine Ferrara, PhD, Professor and Division Chief, Molecular Imaging Program, Stanford University (TBC)
	Raluca Mititelu, MD, PhD, Lecturer, University of Medicine and Pharmacy Carol Davila Bucharest Clinic of Nuclear Medicine, Central University Emergency Military Hospital Bucharest, Romania (TBC)
2:15PM	Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
2:15PM	<i>Topic 1A: The Earlier Use of Radio Pharmaceuticals in Prostate Cancer:</i> Marc B. Garnick, MD, Director of Cancer Community Services, BIDMC; Gorman Brothers Professor of Medicine at Harvard Medical School; and Editor-in-Chief, Harvard Medical School Prostate Disease Report

2:25PM	Q & A
2:27PM	<i>Topic 1B: Sequencing of Treatment:</i> Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors (TBC)
2:37PM	Q & A
2:40PM	<i>Topic 1C: Novel Systemic Treatment: Recent Advances and Future Directions in Targeted Treatment:</i> Daniel P. Petrylak, MD, Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University (TBC)
2:50PM-3:30PM	COFFEE BREAK
3:30PM	<i>Topic 1D: Emerging Advances in Precision Radiation Treatment and Immunotherapy – Fireside Chat:</i> Steven E. Finkelstein, MD, and Patrick Soon-Shiong, MD, Executive Chairman and Global Chief Scientific and Medical Officer, ImmunityBio
3:45PM	Q & A
3:50PM-4:20PM	<i>Panel Discussion: Standard and Emerging Treatment</i>
4:20PM	Topic 2: Molecular Imaging and Theranostics
4:20PM	<i>Topic 2A: Radiopharmaceutical Design and Molecular Imaging:</i> Katherine Ferrara, PhD (TBC)
4:30PM	Q & A
4:32PM	<i>Topic 2B: Radiologic Perspective on Integration of Molecular Imaging and Treatment:</i> Andrei Iagaru, MD, Professor of Radiology and Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program, Stanford University (TBC)
4:42PM	Q & A
4:44PM	<i>Topic 2C: PSMA-Targeted Therapy - Clonal Heterogeneity, Neuroendocrine Differentiation, and Finding the Right Sequence of Systemic Treatment:</i> Vikas Prasad, MD, PhD, Associate Professor of Radiology, Director of Clinical Theranostics, Center for Clinical Theranostics Research, Division of Nuclear Medicine, Mallinckrodt Institute of Radiology; and Co-Chair, Theranostics Program, Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri
4:54PM	Q & A
4:56PM	<i>Topic 2D: Emerging Radioligand Therapy and Prostate Cancer:</i> Ilya Gipp, MD, PhD
5:06PM	Q & A
5:08PM-5:30PM	<i>Panel Discussion: Molecular Imaging and Theranostics</i>
5:30PM-5:45PM	General Discussion: Speakers, Moderators
5:45PM-6:30PM	VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)

THURSDAY, OCTOBER 8, 2026

8:00AM **SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes**

Moderators:

David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York (TBC)

Giovanni Lughezzani, MD, Staff Physician, Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (MI), and Associate Professor, Humanitas University, Milan, Italy

Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine

Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine

8:10AM **Topic 1: Overview of Focal Treatment:** Mark Emberton, MD

8:20AM Q & A

8:22AM **Topic 2: Patient Selection for Targeted Treatment**

8:22AM *Topic 2A: Urologic Perspective:* Peter Pinto, MD, National Institutes of Health, Director of the Urologic Oncology Fellowship Program at the National Cancer Institute, Sponsored by Profound Medical

8:32AM Q & A

8:34AM *Topic 2B: The Multicentre Trials on Focal Therapy:* Jurgen Futterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen; and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands

8:44AM Q & A

8:46AM *Topic 2C: Quantitative MRI Reading, AI Derived Algorithms for ECE/BCR, and AI Use in MRI Directed Treatment of Prostate Cancer:* Victoria Bird, MD, President and Founder of Urologic Integrated Care, Gainesville, FLA; Staff Urologic Surgeon, HCA Florida North Florida Hospital; CEO, Urology Division, Research Group, National Medical Association; and Former Affiliate Professor of Engineering, Biomedical Engineering, College of Engineering, and Former Assistant Professor, Department of Urology, College of Medicine, University of Florida

8:56AM Q & A

8:58AM **Topic 3: Micro-Ultrasound and Irreversible Electroporation (IRE) for Treatment of Prostate Cancer:** Xiaosong Meng, MD, PhD, Assistant Professor and Dedman Family Scholar in Clinical Care, Department of Urology, University of Texas Southwestern Medical Center

9:08AM Q & A

9:10AM **Topic 4: Comparative Analysis and Clinical Utility of the Current Modalities in Therapeutic Ablation for Prostate Cancer:** Alessandro Marquis, MD, FEBU, Urology Clinic, Department of Surgical Sciences, Molinette Hospital and University of Turin

9:20AM Q & A

9:22AM-9:40AM *Panel Discussion*

9:40AM-10:10AM **COFFEE BREAK**

10:10AM **Topic 5: Addressing Fundamental Challenges in Clinical Evaluation, Acceptance and Adoption of Image-Targeted Treatment- Perspective from the AdMeTech Foundation's International Working Group**

10:10AM *Review and Update – Imaging for Improving Post-Ablation Assessment and Developing Short-Term Patient Outcomes:* Faina Shtern, MD

10:20AM *Current Approaches to MRI Reporting After Focal Treatment:* Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University

10:30AM-10:40AM *Comments:* Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of Medical Sciences, University College London, Honorary Consultant Radiologist, University College London Hospitals; and Sangeet Ghai, MD, Professor and Trachtenberg Haque Chair in Image Guided Prostate Therapy Research, Director of Research, Joint Department of Medical Imaging, University Health Network – Mt Sinai Hospital – Women's College Hospital, University of Toronto, Canada (TBC)

10:40AM Q & A

10:45AM *A New Scoring System for PSMA Imaging and PSMA/MRI Integration for Patient Evaluation after Focal Treatment: Development and Preliminary Data:* Giovanni Lughezzani, MD

10:55AM Q & A

11:00AM-11:30AM	Panel on MRI Reporting Post Focal Treatment –Rationale, Background, & Recommendations: Sangeet Ghai, MD (TBC), Francesco Giganti (TBC), and Daniel Margolis, MD
11:30AM-12:00PM	Panel on Molecular Imaging Post Focal Treatment – Rationale, Background, Emerging Data and Next Steps: Andrei Iagaru, MD (TBC); Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland (TBC); and Andrea Di Giorgio, MD
12:00PM-12:30PM	VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)
12:30PM-1:00PM	LUNCH BREAK
1:00PM-1:30PM	KEYNOTE PRESENTATIONS
1:30PM	Precision Care and Health Disparities in Prostate Cancer - Risk Assessment in Black Men: Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health; and Faina Shtern, MD
1:45PM	Q & A
1:50PM	Do We Understand the Prostate Cancer Genome?: Paul Boutros, PhD, MBA
2:05PM	Q & A
2:10PM-2:40PM	PRESENTATION OF WINNING ABSTRACTS
2:40PM-4:00PM	GENERAL DISCUSSION
4:00PM	ADJOURN